Health Care
As pandemic boom fades, Moderna’s market momentum reverses
Moderna, which led the biotechnology sector’s pandemic-driven surge, struggles to keep pace with the market.
Section
Pharmaceuticals
Company Insights
Eli Lilly races to fend off competitors in weight-loss drug market
Eli Lilly bulks up on supply and lawsuits to ward off competition in the booming weight loss market
Pharmaceuticals
Eli Lilly stock falls 13% after disappointing sales for Mounjaro and Zepbound in the third quarter
Eli Lilly lowered its revenue forecasts for the full year after an inventory drawdown by wholesalers weighed on sales for blockbuster weight loss and diabetes drugs.
COVID-19
Small biotech poised for a cure after years of plunging stock
Small-cap biotech stocks plundered after a 2021 wild-run, but investors are hopeful that interest rate cuts and positive test results in oncology and autoimmune treatments will be the right prescription for the biopharma market.
Pfizer
Pfizer is looking for its next blockbusters after Covid. Could one of them be treating cancer?
Photo: Wikimedia Commons Covid made Pfizer a household name and sent its revenues and profits soaring.
COVID-19
Pfizer Sales Down As Demand for Covid Products Fall
Photo credit:Wikimedia Commons Pfizer reported a loss in the third quarter as it tries to adapt to the faltering demand on its Covid-19 drug and vaccines.
Insulin Price Caps and Tough Litigation Won’t Bury Big Pharma
Federal legislative overhaul of the healthcare sector is throwing a wrench into Big Pharma’s growth this fall, but companies are expected to weather the storm in a market hungry for new drug therapies.